AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17604958 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent pacemaker (PPM)
Number of subjects: 248
Study 17604958 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 248
Study 16373466 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive CD-ROM program on safe medication practices
Number of subjects: 30
Study 16373466 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 12450908 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (1 dose of 60 mg Fe/d)
Number of subjects: 50
Study 12450908 — intervention group
Group type: COMPARATOR
Intervention: Weekly iron supplementation (2 doses of 60 mg Fe once weekly)
Number of subjects: 50
Study 10510150 — intervention group
Group type: COMPARATOR
Intervention: Placebo antitussive preceded at 1 h by placebo inhibitor
Number of subjects: 22
Study 10510150 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral DEX preceded at 1 h by placebo inhibitor (DEX30)
Number of subjects: 22
Study 10510150 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg oral DEX preceded at 1 h by placebo inhibitor (DEX60)
Number of subjects: 22
Study 10510150 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral DEX preceded at 1 h by 50 mg oral quinidine sulphate (QDEX30)
Number of subjects: 22
Study 8834127 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment (prednisone 10-15 mg/day) plus supplementary home oxygen therapy (mean 16.4 h/day) for 4 years.
Number of subjects: 18
Study 8834127 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (prednisone 10-15 mg/day) without home oxygen therapy for 4 years.
Number of subjects: 18
Study 2036669 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 58
Study 2036669 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 58
Study 2036669 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 58
Study 2036669 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and Metoprolol (higher doses)
Number of subjects: 58
Study 7016223 — intervention group
Group type: COMPARATOR
Intervention: Alkeran (600 mg/m2 x 5 days every 6 weeks)
Number of subjects: 406
Study 7016223 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkeran
Number of subjects: 406
Study 7016223 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine, Thiotepa, Methotrexate and 5 Fu (VTMF)
Number of subjects: 406
Study 7016223 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Methotrexate, 5 Fu (CMF)
Number of subjects: 406
Study 7016223 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF VP (Vincristine and Prednisone)
Number of subjects: 406
Study 31033457 — intervention group
Group type: EXPERIMENTAL
Intervention: Theraband exercise group (TBG)
Number of subjects: 27
Study 31033457 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 27
Study 30859955 — intervention group
Group type: EXPERIMENTAL
Intervention: ALKS 3831
Number of subjects: 403
Study 30859955 — intervention group
Group type: EXPERIMENTAL
Intervention: OLZ
Number of subjects: 403
Study 30859955 — intervention group
Group type: COMPARATOR
Intervention: PBO
Number of subjects: 403
Study 29259196 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide (N2O)
Number of subjects: 47
Study 29259196 — intervention group
Group type: COMPARATOR
Intervention: Control (without inhaled nitrous oxide)
Number of subjects: 47
Study 27069173 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hydration with 15 mEq magnesium sulfate (Mg-hydration group)
Number of subjects: 74
Study 27069173 — intervention group
Group type: COMPARATOR
Intervention: Non-pre-hydration (non-Mg-hydration group)
Number of subjects: 74
Study 24859114 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted diets with varying glycemic load (GL)
Number of subjects: 0
Study 24859114 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted diets with provided food for the first six months
Number of subjects: 0
Study 24859114 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted diets with self-selected food after six months
Number of subjects: 0
Study 24859114 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted diets with lesser amounts of weight loss
Number of subjects: 0
Study 22609644 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous spinal anesthesia (CSA)
Number of subjects: 45
Study 22609644 — intervention group
Group type: COMPARATOR
Intervention: Propofol target-controlled infusion (TCI)
Number of subjects: 45
Study 22609644 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (SEVO)
Number of subjects: 45
Study 19248130 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy with infliximab
Number of subjects: 508
Study 19248130 — intervention group
Group type: COMPARATOR
Intervention: Initial combination therapy with prednisone
Number of subjects: 508
Study 19248130 — intervention group
Group type: COMPARATOR
Intervention: Step-up combination therapy
Number of subjects: 508
Study 19248130 — intervention group
Group type: COMPARATOR
Intervention: Sequential monotherapy
Number of subjects: 508
Study 17884605 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered SCREEN II
Number of subjects: 134
Study 17884605 — intervention group
Group type: COMPARATOR
Intervention: Telephone-administered SCREEN II
Number of subjects: 134
Study 15066083 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions on Frailty recommendations for screening, recruiting, evaluating, and retaining frail older persons in clinical trials.
Number of subjects: 0
Study 15066083 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies to improve retention and compliance in clinical trials.
Number of subjects: 0
Study 15066083 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation of cost and sample size for clinical trials.
Number of subjects: 0
Study 15066083 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional research needs identified.
Number of subjects: 0
Study 11741732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethylenediaminetetraacetic acid (EDTA) for 30s
Number of subjects: 110
Study 11741732 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid gel for 60s
Number of subjects: 110
Study 11741732 — intervention group
Group type: COMPARATOR
Intervention: No etching
Number of subjects: 110
Study 10443656 — intervention group
Group type: COMPARATOR
Intervention: HP FSH (150 IU/day) alone (group A)
Number of subjects: 20
Study 10443656 — intervention group
Group type: EXPERIMENTAL
Intervention: HP FSH (150 IU/day) combined with hCG (50 IU/day) (group B)
Number of subjects: 20
Study 7798679 — intervention group
Group type: EXPERIMENTAL
Intervention: Towne vaccine (approximately 500 pfu)
Number of subjects: 80
Study 7798679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 7798679 — intervention group
Group type: COMPARATOR
Intervention: Naturally seropositive subjects
Number of subjects: 80
Study 7798679 — intervention group
Group type: EXPERIMENTAL
Intervention: Towne vaccine
Number of subjects: 80
Study 7798679 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild type infection
Number of subjects: 80
Study 11527124 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 mg once a day for 8 weeks, dosage doubled after 4 weeks if DBP > 90 mm Hg)
Number of subjects: 46
Study 11527124 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg once a day for 8 weeks, dosage doubled after 4 weeks if DBP > 90 mm Hg)
Number of subjects: 46
Study 11527124 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 46
Study 11527124 — intervention group
Group type: COMPARATOR
Intervention: Acebutolol
Number of subjects: 46
Study 372255 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse
Number of subjects: 29
Study 372255 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 29
Study 30849925 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based community reinforcement approach (CRA) plus contingency management
Number of subjects: 0
Study 30849925 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient care
Number of subjects: 0
Study 28327174 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-h group-based intervention for students, two 2-h training workshops for teachers, provision of light PA equipment in classrooms.
Number of subjects: 33
Study 28327174 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptability ratings of sessions for students (M = 6.29, scale 1-7).
Number of subjects: 33
Study 28327174 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective measures of PA and SB (7-day accelerometry) conducted at T1, T3, and T4.
Number of subjects: 33
Study 28327174 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported PA and sitting measured at baseline (T1), mid-intervention (T2), post-intervention (T3), and 6 months after baseline (T4).
Number of subjects: 33
Study 25471197 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg caffeine
Number of subjects: 0
Study 25471197 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee (expectation of caffeine)
Number of subjects: 0
Study 25471197 — intervention group
Group type: COMPARATOR
Intervention: Bitter lemon soda (no expectation of caffeine)
Number of subjects: 0
Study 25471197 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (expected and administered)
Number of subjects: 0
Study 23429905 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (300 mL)
Number of subjects: 17
Study 23429905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dräger DrugTest 5000
Number of subjects: 17
Study 23429905 — intervention group
Group type: COMPARATOR
Intervention: DrugTest 5000
Number of subjects: 17
Study 22013793 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinluotong Tablet (XLTT), four tablets each time, three times a day
Number of subjects: 240
Study 22013793 — intervention group
Group type: COMPARATOR
Intervention: Yangxinshi Tablet (YXST), three tablets each time, three times a day
Number of subjects: 240
Study 22013793 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinluotong Tablet (XLTT)
Number of subjects: 240
Study 22013793 — intervention group
Group type: COMPARATOR
Intervention: Yangxinshi Tablet (YXST)
Number of subjects: 240
Study 19242286 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a alone or with ribavirin
Number of subjects: 114
Study 17938390 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 100 mg
Number of subjects: 39876
Study 17938390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39876
Study 14607578 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (leuprolide acetate; 1 mg/d, SC)
Number of subjects: 20
Study 14607578 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA; 20 mg/d)
Number of subjects: 20
Study 14607578 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA during second 12 weeks (protocol B)
Number of subjects: 20
Study 14607578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10666141 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdialysis with probes inserted in the vastus lateralis muscle measuring interstitial K(+) concentrations
Number of subjects: 0
Study 8653729 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (330 mg)
Number of subjects: 10
Study 8653729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1613709 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal knee irrigation
Number of subjects: 77
Study 6089555 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg daily
Number of subjects: 53
Study 6089555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 3094059 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.65 mg/kg)
Number of subjects: 0
Study 3094059 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (200 micrograms)
Number of subjects: 0
Study 3094059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31286252 — intervention group
Group type: EXPERIMENTAL
Intervention: Faculty-led instruction
Number of subjects: 44
Study 31286252 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer tutor-led instruction
Number of subjects: 44
Study 31286252 — intervention group
Group type: EXPERIMENTAL
Intervention: Holography-augmented instruction
Number of subjects: 44
Study 31286252 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison
Number of subjects: 44
Study 31286252 — intervention group
Group type: COMPARATOR
Intervention: Overall program evaluation
Number of subjects: 44
Study 29896798 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion to achieve target MAP of 75 mm Hg
Number of subjects: 10
Study 29896798 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion to achieve target MAP of 90 mm Hg
Number of subjects: 10
Study 29896798 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine infusion to achieve target MAP of 60 mm Hg
Number of subjects: 10
Study 25730591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance Movement Therapy (DMT) during radiotherapy (6 sessions at 90 minutes each)
Number of subjects: 104
Study 25730591 — intervention group
Group type: COMPARATOR
Intervention: Dance Movement Therapy (DMT) after radiotherapy (1 to 2 months post-treatment)
Number of subjects: 104
Study 24668261 — intervention group
Group type: EXPERIMENTAL
Intervention: Harp therapy during embryo transfer
Number of subjects: 181
Study 24668261 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 181
Study 24668261 — intervention group
Group type: EXPERIMENTAL
Intervention: Harp therapy
Number of subjects: 181
Study 23412077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemia control
Number of subjects: 8929
Study 23412077 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemia control
Number of subjects: 8929
Study 23412077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive participants who never took insulin or TZD
Number of subjects: 8929
Study 23412077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive participants who began insulin or TZD after enrollment
Number of subjects: 8929
Study 19941160 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg) for 12 weeks followed by Anastrozole (1 mg) for 12 weeks
Number of subjects: 94
Study 19941160 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg) for 12 weeks followed by Letrozole (2.5 mg) for 12 weeks
Number of subjects: 94
Study 19941160 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (after 6 months of AI therapy)
Number of subjects: 94
Study 19941160 — intervention group
Group type: COMPARATOR
Intervention: Prior Tamoxifen therapy
Number of subjects: 94
Study 17964821 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional stripping
Number of subjects: 160
Study 17964821 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryostripping
Number of subjects: 160
Study 17964821 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study 16096715 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG) - low-volume high-resistance strength training and high-impact aerobics, supplemented with calcium and vitamin D.
Number of subjects: 78
Study 16096715 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - non-training, supplemented with calcium and vitamin D.
Number of subjects: 78
Study 12795585 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention program for depressive and anxious symptoms
Number of subjects: 189
Study 12795585 — intervention group
Group type: COMPARATOR
Intervention: Usual health education classes (Control)
Number of subjects: 189
Study 11190602 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric tests for stratum interaction with covariates
Number of subjects: 0
Study 11190602 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric tests for stratum interaction with baseline hazard functions
Number of subjects: 0
Study 9033825 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ilio-hypogastric nerve block in 21 patients
Number of subjects: 42
Study 9033825 — intervention group
Group type: COMPARATOR
Intervention: No ilio-hypogastric nerve block in 21 patients (Control)
Number of subjects: 42
Study 1793238 — intervention group
Group type: EXPERIMENTAL
Intervention: HeNe laser treatment (wave-length, 632.8 nm; beam power, 6 mW; continuous emission, energy density, 4 J/cm2)
Number of subjects: 46
Study 1793238 — intervention group
Group type: COMPARATOR
Intervention: Placebo HeNe laser treatment
Number of subjects: 46
Study 6430689 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance-improving strategies (patient counselling, special medication container, self-recording of medication intake and seizures, mailed reminders)
Number of subjects: 53
Study 6430689 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 53
Study 30803749 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (4 g daily for 8 weeks)
Number of subjects: 73
Study 30803749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 29396070 — intervention group
Group type: EXPERIMENTAL
Intervention: l-homoarginine (l-hArg) supplementation
Number of subjects: 20
Study 29396070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26792024 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal infusion of HCA (2800 mg in water)
Number of subjects: 20
Study 26792024 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 20
Study 25172769 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP plus best supportive care (BSC)
Number of subjects: 278
Study 25172769 — intervention group
Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 278
Study 23285095 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine + sulfadoxine‐pyrimethamine
Number of subjects: 0
Study 23285095 — intervention group
Group type: COMPARATOR
Intervention: None (control group not specified)
Number of subjects: 0
Study 20307827 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic empowerment intervention (support and incentives to save money toward secondary education)
Number of subjects: 277
Study 20307827 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control condition)
Number of subjects: 277
Study 17971533 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive treatment strategies
Number of subjects: 0
Study 17971533 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential randomization
Number of subjects: 0
Study 15576850 — intervention group
Group type: EXPERIMENTAL
Intervention: PON1 genotypes (L55M, Q192R, -107C/T, -162A/G, -824G/A, and -907G/C)
Number of subjects: 302
Study 15576850 — intervention group
Group type: EXPERIMENTAL
Intervention: PON1 levels
Number of subjects: 302
Study 15576850 — intervention group
Group type: EXPERIMENTAL
Intervention: PON1 activity (paraoxonase, diazoxonase, arylesterase)
Number of subjects: 302
Study 12167681 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (200 to 240 units)
Number of subjects: 126
Study 12167681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 10376916 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 degrees C
Number of subjects: 138
Study 10376916 — intervention group
Group type: COMPARATOR
Intervention: 60 degrees C
Number of subjects: 138
Study 8897081 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (2 g b.i.d. for 5 days)
Number of subjects: 14
Study 8897081 — intervention group
Group type: COMPARATOR
Intervention: Control (absence of sucralfate)
Number of subjects: 14
Study 1642342 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg intravenous bolus of dexamethasone
Number of subjects: 700
Study 1642342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study 6427477 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg luteinizing hormone releasing hormone agonist daily
Number of subjects: 23
Study 6427477 — intervention group
Group type: COMPARATOR
Intervention: 3 mg diethylstilbestrol per day
Number of subjects: 23
Study 30865980 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified breast milk until 52 weeks of gestational age (GA)
Number of subjects: 158
Study 30865980 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding according to recommendations in developing countries
Number of subjects: 158
Study 30865980 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for 4-6 months or low protein follow-up formulas
Number of subjects: 158
Study 30865980 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein formulas during infancy
Number of subjects: 158
Study 30865980 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein intake during the first 2 years
Number of subjects: 158
Study 29327313 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory therapy (four types of exercises: touch, proprioception, vibration, stereognosis)
Number of subjects: 59
Study 29327313 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59
Study 29327313 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory therapy
Number of subjects: 59
Study 26785711 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-restricted, semi-vegetarian diet with vitamin D and dietary supplements (fish oil, lipoic acid, omega-3 polyunsaturated fatty acids, resveratrol, multivitamin complex)
Number of subjects: 43
Study 26785711 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-restricted, semi-vegetarian diet with vitamin D and dietary supplements
Number of subjects: 43
Study 26785711 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly administration of 5000 IU vitamin D
Number of subjects: 43
Study 26785711 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restriction only
Number of subjects: 43
Study 24628753 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus EEG (microEEG)
Number of subjects: 149
Study 24628753 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 149